The U.S. Food and Drug Administration has approved a long-acting testosterone injection despite growing concerns and evidence that such therapies greatly increase the risks of cardiovascular problems in those that use them.
The FDA approved Aveed, produced by Endo Pharmaceuticals of Ireland, even amid its own recently announced review of all so-called Low T drug replacement therapies. That review, announced in January, came in light of two studies that found that heart attacks, strokes and other cardiovascular problems doubled, and sometimes tripled, in older men who were on testosterone drugs such as AndroGel.
An injection of Aveed reportedly last 10 weeks as opposed to other brands that are taken by gel or patch form weekly or every two weeks.
After approving the drug on March 7, an FDA spokesman said that the agency's current view of the benefits of testosterone therapy, including Aveed, is that it outweighs the known risks when used as directed in patients for whom the drug is indicated.
Ross Feller Casey, a leading personal injury law firm, is investigating potential testosterone lawsuits against the manufacturers of Low T therapies, including Fortesta, which is also made by Endo Pharmaceuticals.
If you or a loved one has suffered a heart attack, stroke or any other serious cardiovascular issues while on or after taking AndroGel or another testosterone drug, please contact the Ross Feller Casey testosterone lawyers for a free case evaluation.
To learn more, go to www.rossfellercasey.com/practice-areas/lowtlawsuit/